Milestone Scientific Inc. (MLSS)

In July 2025, Milestone Scientific appointed Shanth Thiyagalingam to its Board of Directors. In October 2025, the company provided a business update highlighting operational progress and growth initiatives, also reporting a reduction in operating expenses by approximately 20% compared to Q3 2024. In November 2025, Milestone Scientific reported its Q3 2025 financial results, showing a smaller-than-expected loss per share and exceeding revenue forecasts; analysts maintained a "Speculative Buy" recommendation but lowered the price target. In December 2025, the stock price target was further decreased by 50% to $1.02 by analysts. In January 2026, Milestone Scientific launched The Wand® Ambassador Program to expand peer engagement and accelerate market adoption in dentistry; the stock price was $0.29 as of January 9, 2026.

Information regarding specific demand seasonality for Milestone Scientific, Inc.'s products and services was not found in the provided search results.

Milestone Scientific, Inc. is a biomedical technology company focused on designing, developing, and commercializing diagnostic and therapeutic injection technologies for the medical and dental sectors. The company's core mission is to enhance the precision, efficiency, and safety of medical and dental procedures through technological solutions, aiming for painless and precise injections. Its major products include the CompuDent® and STA Single Tooth Anesthesia System® (The Wand®), the CompuFlo® Epidural System, and the CathCheck Verification System. Milestone Scientific generates revenue through the sale of its capital equipment systems and the recurring sale of single-use disposable handpieces and cartridges.

Milestone Scientific maintains a market presence through direct sales and partnerships with distributors globally. The company is headquartered in Roseland, New Jersey, United States. Its technologies are distributed across North America, Europe, Latin America, and parts of Asia, including the United States, China, Canada, and several European and Middle Eastern countries.

Milestone Scientific's brand reputation has been influenced by positive developments and challenges. Positive developments include strong Q3 2024 earnings, improvement in gross margin in Q1 2024, a smaller-than-expected loss and a revenue beat in Q3 2025, Medicare reimbursement for its CompuFlo Epidural System, and the launch of The Wand® Ambassador Program. Challenges include a substantial decline in stock price and decreased price targets by analysts.

Milestone Scientific Inc. has a public company ownership structure where a significant majority of shares are held by the retail public, with strategic direction influenced by insiders and a concentrated institutional base. Major institutional owners include Vanguard Group Inc., Geode Capital Management LLC, and Renaissance Technologies LLC, among others.